Adicet’s γδ CAR T competitive with other allogeneics at lower dose

Initial readouts from Adicet’s lead program suggest the allogeneic γδ CAR T therapy could match or beat off-the-shelf candidates based on conventional αβ T cells, potentially at lower doses.

The data are also among the most advanced readouts for therapies based on γδ T cells, whose stress signal-detecting, HLA-independent TCR makes the cells a good fit for allogeneic therapies. Therapies based on γδ T cells sparked a wave of company creation about six years ago, and have recently seen a cluster of trial starts, preliminary Phase I data and a consummated build-to-buy deal...